Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


After License Deal for Letermovir: Head-to-head Phase 2 Trial Initiated by AiCuris to Demonstrate Superiority of its Novel Drug Pritelivir vs. Valacyclovir for Treatment of Genital Herpes

WUPPERTAL, Germany, November 27, 2012 /PRNewswire/ --

Cross-Reference: More Informations are available at: http://www.presseportal.de/pm/106935/

AiCuris announced today that it has started the second clinical efficacy trial with pritelivir (AIC316), its novel anti-herpes simplex virus (HSV) drug in development. After the first trial showed a high efficacy of pritelivir against genital herpes, the present trial AIC316-01-II-02 (NCT01658826, http://www.clinicaltrials.gov) is designed to prove superiority of pritelivir vs. valacyclovir in reducing genital HSV shedding. http://www.aicuris.com/10/News_Publications.htm

"We expect to see superior efficacy of pritelivir in direct comparison with valacyclovir", comments Dr. Alexander Birkmann, project leader for pritelivir. "Reduction of viral shedding is not only extremely relevant for the patients to reduce the risk of transmitting genital herpes to their partner, which is only reduced by 50% with present therapies. It is also a predictor for the potency of pritelivir to treat or even prevent the development of herpes lesions." Furthermore, pritelivir offers very convenient dosing regimens for patients: only one pill for treatment of a herpes episode.

About pritelivir

Pritelivir is a potent inhibitor of HSV replication. It has a new mode of action (inhibition of the viral helicase-primase enzyme complex) and a favorably long plasma half-life. It also stems from a novel chemical class. Pritelivir is active against both labial and genital herpes virus strains and retains activity against viruses which have become resistant to marketed drugs.

In the previous trial pritelivir exhibited a highly significant and dose dependent reduction of viral shedding, of the amount of virus shed, and of clinical lesions under treatment.

Contact:

http://www.Aicuris.com

AiCuris GmbH & Co. KG    

Katja Woestenhemke    
Friedrich-Ebert-Str. 475/Building 302    
42117 Wuppertal
Phone:  +49-202-317-63-1176
Fax:    +49-202-317-63-1177
E-mail: press@aicuris.com


About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
These days attacks are becoming more sophisticated and more common. Mobile devices, cloud computing and the Internet of Things have increased the number of access points that must be secured. To complicate matters, CISOs are been directed to secure system without compromising the seaml...
There's an impulse to roll one's eyes and think of legacy applications as problematic, almost by definition. They're old, and they may run on hardware that's slower or more difficult to maintain. But in many instances, that's too simplistic an assessment. Would you respond the same way...
While marketing automation by itself is extremely powerful and is mostly based in the cloud, the effectiveness of such strategies can be enhanced by leveraging the benefits that cloud computing offers. Not too long ago, marketers had to inevitably choose between two options - keep mark...
My daughter is taking a class on entrepreneurship in her senior year of high school (yep, that’s the Silicon Valley for you). She loves the class, the energy of the teacher, and the creativity associated with the subject. As a result, we have had several conversations about what does i...
The origins of SAP GRC software goes back decades, but adoption has been slow. But with the rigor of modern compliance regimes like SOX, coupled with the sheer volume and complexity of online transactions, there’s been an accelerating movement away from document-centric review processe...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE